21 completed, 11 recruiting, 4 active not recruiting, 4 unknown. 14 Phase 2, 9 Not applicable, 7 Phase 1, 4 Phase 3, 4 Phase 4.
Follow Non-cystic Fibrosis Bronchiectasis: new trials by email Literature Review of Non-cystic Fibrosis Bronchiectasis trials Research Report on Non-cystic Fibrosis Bronchiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis Galvokimig, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | UCB Biopharma SRL | 300 | 2026-08-05 | 2026-10-27 |
| A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa Rev-56 for Inhalation, Placebo: Normal saline - Healthy Participants, Non-cystic Fibrosis Bronchiectasis | Phase 1 | Active not recruiting | Revagenix, Inc. | 64 | 2026-07-13 | 2026-10-14 |
| Azithromycin to Modify Bronchiectasis Exacerbation Risk Standard Bronchiectasis Care, Azithromycin, Matching Placebo - Non-cystic Fibrosis Bronchiectasis, Bronchiectasis Adult | Phase 4 | Recruiting | Assiut University | 500 | 2026-06-29 | 2026-09-24 |
| A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis SAR445399, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Suspended | Sanofi | 70 | 2026-06-08 | 2026-07-29 |
| A Clinical Study of RSS0343 in Healthy Subjects RSS0343 Tablets, RSS0343 Tablets Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 1 | Completed | Reistone Biopharma Company Limited | 48 | 2026-01-08 | 2026-08-17 |
| A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE Participant Follow-up - Non-cystic Fibrosis Bronchiectasis | Active not recruiting | AstraZeneca | 251 | 2025-10-27 | 2026-09-08 | |
| A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis HSK31858, tablet - Non-cystic Fibrosis Bronchiectasis | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 669 | 2025-09-28 | 2026-06-01 |
| BASE: Bronchiectasis Severity and Exacerbation Risk Study Bronchiectasis, Non-cystic Fibrosis Bronchiectasis | Recruiting | Assiut University | 750 | 2025-09-11 | 2026-05-20 | |
| Bronchiectasis Phenotype Identification Model Bronchiectasis, Non-cystic Fibrosis Bronchiectasis | Recruiting | Assiut University | 750 | 2025-09-11 | 2026-05-20 | |
| Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB) CSL787, Placebo, Nebulizer - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | CSL Behring | 180 | 2025-09-03 | 2026-10-19 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis XH-S004 20 mg, XH-S004 40 mg, Placebo - Non-Cystic Fibrosis Bronchiectasis | Phase 2 | Active not recruiting | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 234 | 2025-05-30 | 2026-09-25 |
| Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis SIMEOX, Remote Physiotherapy - Non-cystic Fibrosis Bronchiectasis | Not applicable | Recruiting | Physio-Assist | 622 | 2025-02-03 | 2026-07-07 |
| A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease GDC-6988 - Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | Genentech, Inc. | 17 | 2024-11-18 | 2026-10-20 |
| Hypertonic Saline in NCFB 7% Hypertonic Saline via nebulization - Bronchiectasis, Non-cystic Fibrosis Bronchiectasis | Phase 4 | Recruiting | University of North Carolina, Chapel Hill | 20 | 2024-10-23 | 2025-08-13 |
| Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa) RESP302, RESP303 - Non-Cystic Fibrosis Bronchiectasis | Phase 1 / Phase 2 | Active not recruiting | Thirty Respiratory Limited | 60 | 2024-10-16 | 2026-03-10 |
| A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis HSK31858, tablet, Placebo - Non-cystic Fibrosis Bronchiectasis | Phase 3 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 669 | 2024-09-30 | 2024-10-28 |
| A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution - Non-cystic Fibrosis Bronchiectasis | Phase 2 | Recruiting | Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA | 284 | 2024-09-11 | 2026-10-27 |
| Procalcitonin as a Marker of Severity of Non-cystic Fibrosis Bronchiectasis in Children procalcitonin - Non-cystic Fibrosis Bronchiectasis | Unknown | Assiut University | 30 | 2024-07-01 | 2024-04-17 | |
| Impact of Support Groups for Patients With Non-Cystic Fibrosis Bronchiectasis Support Group - Non-cystic Fibrosis Bronchiectasis | Not applicable | Completed | University of California, San Francisco | 42 | 2024-04-01 | 2025-04-06 |
| Early Detection of Pulmonary Exacerbations in Non-cystic Fibrosis Bronchiectasis non interventional - Non-cystic Fibrosis Bronchiectasis | Unknown | Papworth Hospital NHS Foundation Trust | 50 | 2024-03-01 | 2024-02-29 |
Showing 20 of 45. Sign in to see all of them.
Bronchiectasis (13) · Cystic Fibrosis (2) · Pseudomonas Infections (2) · Pulmonary Disease, Chronic Obstructive (2) · Respiratory Aspiration (2) · Fibrosis (1) · Inflammation (1)
Respiratory Tract Diseases (18) · Bronchial Diseases (13) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Lung Diseases (4) · Bacterial Infections (2) · Bacterial Infections and Mycoses (2) · Chronic Disease (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Disease Attributes (2) · Genetic Diseases, Inborn (2) · Gram-Negative Bacterial Infections (2) · Infant, Newborn, Diseases (2) · Infections (2)
brensocatib (3) · Inhalation (2) · Roflumilast (2) · Tablets (2) · Acetylcysteine (1) · Amikacin (1) · Azithromycin (1) · Breathing Exercises (1) · Ciprofloxacin (1) · Lysine Acetyltransferase 5 (1) · Melphalan (1) · Nebulizers and Vaporizers (1) · Probiotics (1) · Saline Solution (1) · Self-Help Groups (1)
Assiut University (4) · Insmed Incorporated (3) · AstraZeneca (2) · Chiesi Farmaceutici S.p.A. (2) · Haisco Pharmaceutical Group Co., Ltd. (2) · Physio-Assist (2) · Qilu Hospital of Shandong University (2) · The University of Hong Kong (2) · Universitaire Ziekenhuizen KU Leuven (2) · All India Institute of Medical Sciences (1) · Aradigm Corporation (1) · Armata Pharmaceuticals, Inc. (1) · Boehringer Ingelheim (1) · CSL Behring (1) · Emory University (1)
United States (16) · China (8) · Germany (8) · United Kingdom (8) · Belgium (6) · Spain (6) · Italy (5) · Poland (5) · Australia (4) · Canada (3) · Denmark (3) · Egypt (3) · France (3) · South Korea (3) · Argentina (2)
Maiada K. Hashem, MD (3) · Ahmad M Shaddad, MD (2) · Aliae A. Hussien, MD (2) · Pieter Goeminne, MD (2) · Yu Li, Professor (2) · Ahmad M. Shaddad, MD (1) · Alaa S. Ali (1) · Alaa S. Ali, MD (1) · Alaa Sayed, MD (1) · Aliae M. Hussien, MD (1) · Anthony Bier, MD (1) · Bryan Taylor, PhD (1) · Carlos Fernandez, MD (1) · Charles L Daley, MD (1)
PMID 30975143, PMID 31433997, PMID 32071136, PMID 32855225, PMID 32897034, PMID 35976570, PMID 37198686, PMID 37538173, PMID 39040578, PMID 39938076, PMID 39951444, PMID 40267423, PMID 41254308, PMID 41519018, PMID 42461571
2015 (2), 2017 (1), 2018 (1), 2019 (1), 2025 (1)